No Prescription |
 |
 | ||
|
CLOPIVAS Plavix |
|
| ||
No Prescription » Prescription Drugs 4 » CLOPIVAS Plavix Reducing the risk of stroke or heart attack in patients who have already had a heart attack or stroke or have other circulatory problems due to narrowing and hardening of the arteries. It also may be used for other conditions as determined by your doctor.Clopidogrel is a platelet aggregation inhibitor. It works by slowing or stopping platelets from sticking to blood vessel walls or injured tissues.Clopidogrel keeps the platelets in your blood from coagulating (clotting) to prevent unwanted blood clots that can occur with certain heart or blood vessel conditions.Clopidogrel is used to prevent blood clots after a recent heart attack or stroke and in people with certain disorders of the heart or blood vessels.Clopidogrel keeps blood platelets slippery and discourages formation of clots thereby improving blood flow to your heart brain and body. The drug is prescribed to reduce the risk of heart attack stroke and serious circulation problems in people with hardening of the arteries or unstable angina (dangerous chest pain) and in people who've already suffered a heart attack or stroke. Buy CLOPIVAS Plavix and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About CLOPIVAS Plavix: Product Type: Prescription Drugs 4 CLOPIVAS ( Plavix Generic Clopidogrel ) CLOPIVAS (Plavix Generic Clopidogrel) Plavix Generic Clopidogrel 75mg 90 Tablets 360 Tablets 180 Tablets Plavix Generic Clopidogrel CLOPIVAS
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
